1254036-01-5

Upstream product

• 1254035-93-2 1-(5-phenyl-1,3,4-oxadiazole-2-carbonyl)-azetidin-3-yl methanesulfonate 
• 53339-53-0 4-mercaptobenzyl alcohol 
• 16691-25-1 ethyl 5-phenyl-1,3,4-oxadiazole-2-carboxylate 
• 1254035-92-1 (3-hydroxyazetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone 

Downstream Products

• 1254036-02-6 (3-(4-(chloromethyl)phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone 
• 1354791-80-2 (3-(4-((dimethylamino)methyl)phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone 
• 1354791-87-9 (3-(4-((3-(hydroxymethyl)azetidin-1-yl)methyl)phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone 

Relevant academic research and scientific papers

(3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS

Disclosed herein are azetidinyl compounds of formula I, as described herein, pharmaceutical compositions comprising an azetidinyl compound, and a method of using an azetidinyl compound in the treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.

THERAPEUTIC AGENTS 713

Disclosed herein are compounds of Formula (I) in which R1, R2, R3, R4, R5, A, X, Y are as described in the specification, their use in pharmaceutical compositions and in methods of treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.